Prior treatment may impact efficacy of ACT-TIL in patients with metastatic melanoma

By | August 20, 2021
Patients with metastatic melanoma that had relapsed on anti-PD-1 therapies or BRAF/MEK inhibitors did not respond as well to an investigational therapy that involves the adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL) as patients naïve to these treatments.